Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-oriented businesses to continue growing.
Moderna rose 11%; Novavax and others, including Inovio Pharmaceuticals (INO), CureVac (NASDAQ:CVAC), and Arcturus Therapeutics (NASDAQ:ARCT), also traded significantly higher. Manufacturers of the COVID-19 vaccination Comirnaty, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), noted more meager increases.
Based on last week's U.S. Centers for Disease Control and Prevention (CDC) data showing increasing COVID-19 activity in most areas and a concurrent rise in seasonal flu, especially among small children, the rally followed last week's Citing their success in lowering serious disease and hospitalization, the CDC advised Americans to get recommended vaccinations.
The organization also underlined how common respiratory syncytial virus (RSV) is in young children. With its mREVIA medicine, Moderna has joined Pfizer's Abysvo and GSK's Arexvy vaccines on the RSV vaccination market. As health authorities stress preventative actions, the increasing need for vaccinations to treat certain respiratory diseases has attracted investment attention in the sector.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。